



The Illinois Medical Bulletin



The Association Between Type 2 Diabetes Mellitus and the Development of Chronic Kidney Disease: A Literature Review of Foundational Evidence

¹A. Bass, ²A. Beard

^{1,2} University of Illinois College of Medicine

Corresponding Email : bassmd39485@gmail.com

Article History :

Received date : 2009/10/12
Revised date : 2009/11/28
Accepted date : 2009/12/09
Published date : 2010/01/13



Copyright: © by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

ABSTRACT

Introduction: Type 2 Diabetes Mellitus (T2DM) has long been recognised as a global health crisis, not only for its metabolic dysregulation but also for its severe long-term complications. Among these, Chronic Kidney Disease (CKD), often termed diabetic nephropathy, is a major cause of morbidity and mortality. This review synthesises the foundational scientific literature published before 2010 that established the causal link between T2DM and the onset and progression of CKD.

Literature Review: Epidemiological data from the late 20th century firmly established T2DM as the leading cause of end-stage renal disease in the developed world. Foundational studies elucidated the natural history of diabetic nephropathy, beginning with glomerular hyperfiltration and progressing to microalbuminuria, overt proteinuria, and an eventual decline in the glomerular filtration rate. The pathophysiological basis was uncovered, identifying chronic hyperglycemia as the primary driver of renal damage through mechanisms such as the

formation of advanced glycation end-products (AGEs), activation of protein kinase C, and upregulation of the renin-angiotensin-aldosterone system (RAAS). Landmark clinical trials, most notably the United Kingdom Prospective Diabetes Study (UKPDS), provided conclusive evidence that intensive glycemic control could significantly reduce the risk of developing microvascular complications, including nephropathy.

Conclusion: The literature reviewed provides unequivocal evidence that T2DM is a primary and direct cause of CKD. The pathway from hyperglycemia to renal failure is well-defined, and interventions aimed at intensive glycemic and blood pressure control were proven to be effective cornerstones for preventing or slowing the progression of diabetic kidney disease.

Keywords: Type 2 Diabetes Mellitus, Chronic Kidney Disease, Diabetic Nephropathy, Glycemic Control, Microalbuminuria.

INTRODUCTION

Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterised by hyperglycemia resulting from insulin resistance and relative insulin deficiency. Its rising prevalence transformed it into a global epidemic throughout the late 20th and early 21st centuries. While the management of blood glucose is the primary therapeutic goal, the clinical significance of T2DM extends far beyond glycemic control. The disease is a catalyst for a host of debilitating microvascular and macrovascular complications, which are the principal sources of morbidity and mortality in affected individuals (Nathan, 1993).

Among the most feared microvascular complications is Chronic Kidney Disease (CKD), also known as diabetic nephropathy. CKD is defined by a progressive loss of kidney function over time, often culminating in end-stage renal disease (ESRD), a condition requiring dialysis or kidney transplantation for survival. By the turn of the century, T2DM had become the single leading cause of ESRD in most developed nations, placing an immense burden on patients, families, and healthcare systems (Ritz and Orth, 1999).

This literature review aims to explore and synthesise the pivotal scientific evidence published prior to 2010 that established the relationship between T2DM and the development of CKD. This review will examine the epidemiological data that quantified the risk, the pathophysiological studies that uncovered the underlying mechanisms of renal damage, and the interventional trial data that formed the basis for modern preventative strategies.

LITERATURE REVIEW

The understanding of diabetic kidney disease evolved from clinical observation to a well-defined pathophysiological entity supported by robust trial evidence. This body of work solidified the link between the metabolic state of diabetes and the structural and functional decline of the kidneys.

The natural history and progression of diabetic nephropathy were extensively described in foundational literature. Mogensen (1983) proposed a staging system that became widely accepted, outlining a progression from an initial stage of glomerular hyperfiltration and renal hypertrophy to the development of incipient nephropathy, characterised by persistent microalbuminuria (small amounts of albumin in the urine). This stage was identified as a critical window for intervention. Without it, patients would advance to overt nephropathy with macroalbuminuria, hypertension, and a steady, predictable decline in glomerular filtration rate (GFR), ultimately leading to ESRD. This framework highlighted microalbuminuria not just as a marker of disease, but as a key risk factor for progression.

The pathophysiological mechanisms linking chronic hyperglycemia to renal injury were a major focus of research. It was established that sustained high blood glucose levels trigger several damaging biochemical pathways. One key mechanism is the non-enzymatic formation of advanced glycation end-products (AGEs), which accumulate in the glomerular basement membrane and mesangium, leading to thickening, cross-linking of collagen, and altered renal structure and function (Brownlee, 1992). Concurrently, hyperglycemia was shown to activate protein kinase C (PKC), which contributes to abnormal blood flow, increased extracellular matrix production, and enhanced vascular permeability. Furthermore, the intrarenal renin-angiotensin-aldosterone system (RAAS) was found to be a critical mediator of damage. Angiotensin II, a key effector of this system, promotes systemic and intraglomerular hypertension, fibrosis, and inflammation, thereby accelerating the progression of nephropathy (Brenner et al., 2001).

Based on this mechanistic understanding, clinical trials sought to prove that modifying these factors could prevent disease. The United Kingdom Prospective Diabetes Study (UKPDS) was a landmark trial for T2DM. One of its key findings, reported by the UKPDS Group (1998), was that intensive blood glucose control with either sulfonylureas or insulin significantly reduced the risk of microvascular endpoints, including a 25% risk reduction in the development of

nephropathy, compared to conventional therapy. This trial provided definitive proof that the degree of glycemic control is directly related to the risk of kidney damage. In addition to glycemic control, the trial also highlighted the critical importance of blood pressure management, showing that tight blood pressure control conferred benefits for microvascular disease that were as great or greater than those from intensive glycemic control. Landmark trials like the RENAAL Study (Brenner et al., 2001), which focused on patients with established T2DM nephropathy, demonstrated that blocking the RAAS with an angiotensin II receptor blocker (ARB) provided significant renal protection beyond that attributable to blood pressure lowering alone, slowing the progression to ESRD.

CONCLUSION

The foundational literature published before 2010 provides a definitive and coherent account of the causal relationship between Type 2 Diabetes Mellitus and Chronic Kidney Disease. Epidemiological studies conclusively established T2DM as the foremost cause of kidney failure, while clinical research meticulously detailed the predictable progression from hyperfiltration to end-stage renal disease.

The underlying pathophysiology was demystified, revealing chronic hyperglycemia as the central culprit that inflicts renal damage through multiple pathways, including the formation of AGEs and the activation of the RAAS. Most importantly, this understanding was translated into effective clinical strategies. Landmark randomised controlled trials, such as the UKPDS and RENAAL studies, provided irrefutable evidence that the course of diabetic nephropathy is not immutable. They proved that intensive control of both blood glucose and blood pressure, specifically with agents that inhibit the renin-angiotensin system, can substantially delay the onset and slow the progression of this devastating complication. This body of work established the standard of care and confirmed that proactive management is the cornerstone of preserving renal function in patients with T2DM.

REFERENCES

Brenner, B.M., Cooper, M.E., de Zeeuw, D., Keane, W.F., Mitch, W.E., Parving, H.H., Remuzzi, G., Snapinn, S.M., Zhang, Z. and Shahinfar, S. (2001) 'Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy', *New England Journal of Medicine*, 345(12), pp. 861-869.

Brownlee, M. (1992) 'Glycation products and the pathogenesis of diabetic complications', *Diabetes Care*, 15(12), pp. 1835-1843.

Mogensen, C.E. (1983) 'Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy', *British Medical Journal (Clinical research ed.)*, 287(6394), p. 753.

Nathan, D.M. (1993) 'Long-term complications of diabetes mellitus', *New England Journal of Medicine*, 328(23), pp. 1676-1685.

Ritz, E. and Orth, S.R. (1999) 'Nephropathy in patients with type 2 diabetes mellitus', *New England Journal of Medicine*, 341(15), pp. 1127-1133.

UK Prospective Diabetes Study (UKPDS) Group. (1998) 'Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)', *The Lancet*, 352(9131), pp. 837-853.